SugarbakerPH: Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol, 1998; 14:254–261.
2.
EsquivelJ, ChuaTC, StojadinovicA, et al.: Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: A multi-institutional study. J Surg Oncol, 2010; 102:565–570.
3.
SugarbakerPH: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of gastrointestinal cancers with peritoneal metastases: Progress toward a new standard of care. Cancer Treat Rev, 2016; 48:42–49.
4.
LarentzakisA, O'DwyerST, BeckerJ, et al.: Referral pathways and outcome of patients with colorectal peritoneal metastasis (CRPM). Eur J Surg Oncol, 2019; 45:2310–2315.
5.
WangW, TanGHC, SkanthakumarT, et al.: Exploring the trend in referrals for consideration of CRS and HIPEC to understand the attitudes of clinicians in the development of a national cancer centre programme in peritoneal disease. Int J Hyperthermia, 2018; 34:551–558.
6.
KyangLS, AlzahraniNA, ValleSJ, et al.: Long-term survival outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy: Single-institutional experience with 1225 cases. J Surg Oncol, 2019; 120:794–802.
7.
van DrielWJ, KooleSN, SikorskaK, et al.: Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med, 2018; 378:230–240.
8.
RovielloF, PintoE, CorsoG, et al.: Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer. J Surg Oncol, 2010; 102:663–670.
9.
VerwaalVJ, van RuthS, de BreeE, et al.: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol, 2003; 21:3737–3743.
10.
FosterJM, SleightholmR, PatelA, et al.: Morbidity and mortality rates following cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy compared with other high-risk surgical oncology procedures. JAMA Netw Open, 2019; 2:e186847.
11.
ShanLL, SaxenaA, ShanBL, et al.: Quality of life after cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy for peritoneal carcinomatosis: A systematic review and meta-analysis. Surg Oncol, 2014; 23:199–210.
12.
DodsonRM, McQuellonRP, MogalHD, et al.: Quality-of-life evaluation after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol, 2016; 23(Suppl 5):772–783.
13.
GaniF, Conca-ChengAM, NettlesB, et al.: Trends in outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Surg Res, 2019; 234:240–248.
14.
GoodmanMD, McPartlandS, DetelichD, et al.: Chemotherapy for intraperitoneal use: A review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy. J Gastrointest Oncol, 2016; 7:45–57.
15.
EliasD, BonnayM, PuizillouJM, et al.: Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: Pharmacokinetics and tissue distribution. Ann Oncol, 2002; 13:267–272.
